Investor Presentaiton

Investor Presentation First six months of 2018. Slide 69 The GLP-1 segment accounts for around 11% of total diabetes care market value in Europe GLP-1 value in DKK billion 8 European GLP-1 market VictozaⓇ exenatide VictozaⓇ value market share in Europe VictozaⓇ exenatide - dulaglutide other 7 16 54 3 1 2 O May 2013 ▪dulaglutide Share of total other GLP-1 value diabetes care market share market 10% 100% CAGR value¹: 21.0% 8% 80% 6% 60% + 4% 40% 2% 20% 0% 0% May 2018 May 2013 1 CAGR for 5-year period Source: IQVIA monthly MAT May, 2018 value figures (DKK) changing diabetes® 56% 31% 12% 2% May 2018 Source: IQVIA monthly MAT May, 2018 value figures (DKK), market share does not add up to 100% due to rounding novo nordisk

View entire presentation